Market Cap : 216.85 M | Enterprise Value : 136.3 M | PE Ratio : At Loss | PB Ratio : 2.71 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
For the three months ended in Dec. 2021, VistaGen Therapeutics's Net Income From Continuing Operations was $-10.54 Mil. Its Depreciation, Depletion and Amortization was $0.32 Mil. Its Change In Working Capital was $-2.73 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.72 Mil. And its Cash Flow from Others was $0.18 Mil. In all, VistaGen Therapeutics's Cash Flow from Operations for the three months ended in Dec. 2021 was $-12.05 Mil.
The historical data trend for VistaGen Therapeutics's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
VistaGen Therapeutics's Cash Flow from Operations for the fiscal year that ended in Mar. 2021 is calculated as:
Cash Flow from Operations | (A: Mar. 2021 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -17.934 | + | 0.118 | + | 3.437 | + | 0 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 2.31 | + | -0.004999999999999 |
= | -12.07 |
VistaGen Therapeutics's Cash Flow from Operations for the quarter that ended in Dec. 2021 is:
Cash Flow from Operations | (Q: Dec. 2021 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -10.535 | + | 0.316 | + | -2.725 | + | 0 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 0.72 | + | 0.178 |
= | -12.05 |
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
VistaGen Therapeutics's net income from continuing operations for the three months ended in Dec. 2021 was $-10.54 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
VistaGen Therapeutics's depreciation, depletion and amortization for the three months ended in Dec. 2021 was $0.32 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
VistaGen Therapeutics's change in working capital for the three months ended in Dec. 2021 was $-2.73 Mil. It means VistaGen Therapeutics's working capital declined by $2.73 Mil from Sep. 2021 to Dec. 2021 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
VistaGen Therapeutics's cash flow from deferred tax for the three months ended in Dec. 2021 was $0.00 Mil.
5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.
VistaGen Therapeutics's cash from discontinued operating Activities for the three months ended in Dec. 2021 was $0.00 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
VistaGen Therapeutics's asset impairment charge for the three months ended in Dec. 2021 was $0.00 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
VistaGen Therapeutics's stock based compensation for the three months ended in Dec. 2021 was $0.72 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
VistaGen Therapeutics's cash flow from others for the three months ended in Dec. 2021 was $0.18 Mil.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By tipranks.com 2022-02-13
By Zacks 2022-02-10
By Fool 2021-06-30
By Seekingalpha 2021-01-24
By Zacks 2021-08-12
By Seekingalpha 2021-06-29
By Zacks 2022-04-05
By Zacks 2021-03-11
By Zacks 2021-06-16
By Zacks 2021-11-10
By Seekingalpha 2021-11-10
By Seekingalpha 2022-02-10
By Zacks 2021-02-11